Kappa-PET Imaging and Naltrexone in Alcohol Drinking Behaviors


Alcohol Drinking

Trial Phase

Phase 1

Trial Purpose and Description

Trial Purpose

The primary purpose of the study is to increase our knowledge of receptor function in the brains of people who are heavy drinkers and taking naltrexone (NTX), a medication that has been approved for the treatment of alcohol dependence. Receptors are special molecules in the brain to which other molecules (neurotransmitters) attach during the normal every-day workings of the brain. Drugs can bind to those receptor molecules as well. Recent evidence suggests that kappa opioid receptors (KOR's) may play an important role in alcohol drinking behavior. This study will try to determine if naltrexone's ability to attach to these receptors is related to its effectiveness. We will use PET (positron emission tomography) for this study. PET is a type of imaging device found in nuclear medicine. It is used for tracking the presence of injected radioactive materials in the body.

Participation Guidelines

21 Years - 50 Years

Eligibility Criteria

Inclusion Criteria:

- Ages 21-50

- Able to read English at 6th grade level or higher and to complete study

- Regular alcohol drinker

Exclusion Criteria:

- Individuals who are seeking alcohol treatment

- Medical conditions that would contraindicate the use of study medication

- Regular use of other substances
Yale University
February 2011
Last Updated:
June 18, 2014
Study HIC#:

Clinicaltrials.gov ID: NCT01625611